174180-42-8

Usage

Uses

1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester is used as a chemical intermediate for the synthesis of various pharmaceuticals and agrochemicals. Its unique molecular structure, which includes a bromomethyl group and an ester functional group, makes it a valuable building block in the development of new compounds with potential therapeutic or pesticidal properties.
Used in Pharmaceutical Industry:
1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester is used as a key intermediate in the synthesis of indazole-based drugs. Its presence in the molecular structure allows for the creation of new drug candidates with potential applications in the treatment of various diseases, such as cancer, inflammation, and neurological disorders.
Used in Agrochemical Industry:
1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester is used as a precursor in the development of novel agrochemicals. Its chemical properties can be exploited to create new pesticides or herbicides with improved efficacy and selectivity, contributing to more sustainable agricultural practices.
Used in Research and Development:
1H-Indazole-1-carboxylicacid,3-(broMoMethyl)-,1,1-diMethylethylester is used as a research compound in academic and industrial laboratories. Its unique structure and reactivity make it an interesting subject for studies in organic chemistry, medicinal chemistry, and materials science, potentially leading to the discovery of new applications and properties.

Upstream product

• 43120-28-1 methyl 1H-indazole-3-carboxylate 
• 3176-62-3 3-methyl-1H-indazole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 174180-72-4 2-methyl-2-propanyl 3-methyl-1H-indazole-1-carboxylate 
• 445-27-2 2'-Fluoroacetophenone 
• 882188-87-6 tert-butyl 3-(hydroxymethyl)-1H-indazole-1-carboxylate 
• 64132-13-4 3-(hydroxymethyl)-1H-indazole 
• 4498-67-3 1H-Indazole-3-carboxylic acid 

Downstream Products

• 871365-74-1 N-(2,2-diethoxyethyl)-N-phenyl 2-(1-tert-butyloxycarbonyl-1H-indazol-3-ylmethyl)malonamide 
• 174181-13-6 2-[3-(1-tert-butoxycarbonyl-1H-indazol-3-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-phenyl-acetamide 
• 179083-74-0 tert-butyl 3-(3-((2,2-diethoxyethyl)(phenyl)amino)-2-(2-(isopropyl(4-methoxyphenyl)amino)-2-oxoethylcarbamoyl)-3-oxopropyl)-1H-indazole-1-carboxylate 
• 1224605-43-9 methyl 3-[[2,2-bis(ethyloxy)ethyl](phenyl)amino]-2-(1H-indazol-3-ylmethyl)-3-oxopropanoate 
• 1228935-05-4 tert-butyl 3-{[6-(2-tert-butoxy-2-oxoethyl)-5-oxo-1-phenyl-5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-4-yl]methyl}-1H-indazole-1-carboxylate 

Relevant academic research and scientific papers

Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities

A series of indazolyl-substituted piperidin-4-yl-aminopyrimidines (IPAPYs) were designed from two potent HIV-1 NNRTIs piperidin-4-yl-aminopyrimidine 3c and diaryl ether 4 as the lead compounds by molecular hybridization strategy. The target molecules 5a-q

Anticancer activity evaluation of indazolyl-substituted piperidin-4-yl-aminopyrimidines

Based on our previous work, a series of indazolyl-substituted piperidin-4-yl-aminopyrimidines, which were firstly used as anti-HIV agents, were evaluated for their anticancer potency in five cancer cell lines. Notably, they exhibited excellent activities

EPHA4 CYCLIC PEPTIDE ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed herein are compounds and methods of use thereof for the modulation of EphA4 receptor activity. In an aspect, is provided a method of treating or preventing a disease or disorder mediated by EphA4, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein, including certain embodiments, or the structural Formula (I), (l-A), (II), (III), (IV), (IV-1), (V), (Vl-A), (Vl-B), (VII-1), (VII-2), (VIII-1), or (VIII-2), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

Supramolecular luminescent lanthanide dimers for fluoride sequestering and sensing

Lanthanide complexes (Ln=Eu, Tb, and Yb) that are based on a C 2-symmetric cyclen scaffold were prepared and characterized. The addition of fluoride anions to aqueous solutions of the complexes resulted in the formation of dinuclear supramolecular compounds in which the anion is confined into the cavity that is formed by the two complexes. The supramolecular assembly process was monitored by UV/Vis absorption, luminescence, and NMR spectroscopy and high-resolution mass spectrometry. The X-ray crystal structure of the europium dimer revealed that the architecture of the scaffold is stabilized by synergistic effects of the Eu-F-Eu bridging motive, πstacking interactions, and a four-component hydrogen-bonding network, which control the assembly of the two [EuL] entities around the fluoride ion. The strong association in water allowed for the luminescence sensing of fluoride down to a detection limit of 24nM.

HIV reverse transcriptase inhibitors

Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

A new and efficient synthesis of 2-azatryptophans

This paper describes a new and simple synthesis of 2-azatryptophans in five steps from 2-ethylaniline. This methodology allows to obtain either the amino acid or the amino ester, according to the treatment and the reaction time, and its scaling up for multigram synthesis.

CCK or gastrin modulating benzo ?b!?1,4! diazepines derivatives

Benzo?b!?1,4!diazepine compounds of formula (I), where R1 is selected from C1 C6 alkyl, C3 -C6 cycloalkyl, phenyl, or substituted phenyl; R2 is selected from C3 -C6 alkyl, C3 C6 cycloalkyl, C3 -C6 alkenyl, benzyl, phenylC1 -C3 alkyl of substituted phenyl; or NR1 R2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C1-6 alkyl C1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R3, R5, and R6 are independently hydrogen or C1-6 alkyl; R4 is C1-6 alkyl or C1-6 alkenyl; R7 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 cycloalkyl, C1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR6 R7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R8 and R9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).

Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists

We previously described a series of 3-(1H-indazol-3-ylmethyl)-1,5- benzodiazepine CCK-A agonists exemplified by compound 1 (GW 5823), which is the first reported binding selective CCK-A full agonist demonstrating oral efficacy in a rat feeding model. In this report we describe analogs of compound 1 designed to explore changes to the CS and N1 pharmacophores and their effect on agonist activity and receptor selectivity. Agonist efficacy in this series was affected by stereoelectronic factors within the C3 moiety. Binding affinity for the CCK-A vs CCK-B receptor showed little dependence on the structure of the C3 moiety but was affected by the nature of the second substituent at CS. Structure-activity relationships at the N1- anilidoacetamide 'trigger' moiety within the C3 indazole series were also investigated. Both agonist efficacy and binding affinity within this series were modulated by variation of substituents on the Nl-anilidoacetamide moiety. Evaluation of several analogs in an in vivo mouse gallbladder emptying assay revealed compound 1 to be the most potent and efficacious of all the analogs tested. The pharmacokinetic and pharmacodynamic profile of 1 in rats is also discussed.